Fibroscan® and Shear Wave correlated well in hepatic fibrosis evaluation of patients with chronic liver diseases "in real life situation"
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc..
BACKGROUND: A new noninvasive medical device based on ultrasound elastography such as the Shear Wave Elastography (SWE) was designed in order to measure the liver hardness. The purpose of this work was to evaluate the correlation of the results of the liver elasticity measurements obtained by Fibroscan® (FS) and SWE for patients with chronic liver diseases.
METHODS: Between January and October 2017, the patients who were followed during this period of time underwent noninvasive assessments of liver fibrosis by SWE in the intercostal spaces during abdominal ultrasound procedures and/or FS. The correlation between FS and SWE was estimated and tested at a 0.05 significance level.
RESULTS: Four hundred and seventy-six patients were included in this study. The main etiologies of chronic liver disease were non alcoholic fatty disease (NAFLD), chronic viral hepatitis B (HBV) and chronic viral hepatitis C (HCV). All patients underwent a SWE and 167 among them underwent a FS procedure. The patients who were followed revealed a median FS measurement of 5.80 kpa (Q25 = 4.90 kPa; Q75 = 8 kPa) and a median SWE measurement of 7.00 kPa (Q25 = 6.10 kPa; Q75 = 8.10 kPa). We could observe a significant correlation between the FS and SWE measurements (0.49; P = .001) in the total cohort. The average absolute difference between the measurements of these 2 methods was of 2.54 kPa (sd = 3.39). There was no significant correlation for patients with NAFLD no matter whether they presented with signs of suspected non alcoholic steatohepatitis (NASH) or not (R = 0.20; P = .108). All patients intending to perform the examination were able to undergo the SWE, allowing 33.3% of the patients who failed the FS to have a noninvasive evaluation of their fibrosis.
CONCLUSION: The SWE technique proved to be as efficient as the FS one for the evaluation of the liver fibrosis in real life situation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:101 |
|---|---|
| Enthalten in: |
Medicine - 101(2022), 32 vom: 12. Aug., Seite e30025 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zougmoré, Honoré Tegwendé [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 16.08.2022 Date Revised 03.01.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/MD.0000000000030025 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM344788571 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM344788571 | ||
| 003 | DE-627 | ||
| 005 | 20231226023600.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/MD.0000000000030025 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1149.xml |
| 035 | |a (DE-627)NLM344788571 | ||
| 035 | |a (NLM)35960072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zougmoré, Honoré Tegwendé |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fibroscan® and Shear Wave correlated well in hepatic fibrosis evaluation of patients with chronic liver diseases "in real life situation" |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.08.2022 | ||
| 500 | |a Date Revised 03.01.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. | ||
| 520 | |a BACKGROUND: A new noninvasive medical device based on ultrasound elastography such as the Shear Wave Elastography (SWE) was designed in order to measure the liver hardness. The purpose of this work was to evaluate the correlation of the results of the liver elasticity measurements obtained by Fibroscan® (FS) and SWE for patients with chronic liver diseases | ||
| 520 | |a METHODS: Between January and October 2017, the patients who were followed during this period of time underwent noninvasive assessments of liver fibrosis by SWE in the intercostal spaces during abdominal ultrasound procedures and/or FS. The correlation between FS and SWE was estimated and tested at a 0.05 significance level | ||
| 520 | |a RESULTS: Four hundred and seventy-six patients were included in this study. The main etiologies of chronic liver disease were non alcoholic fatty disease (NAFLD), chronic viral hepatitis B (HBV) and chronic viral hepatitis C (HCV). All patients underwent a SWE and 167 among them underwent a FS procedure. The patients who were followed revealed a median FS measurement of 5.80 kpa (Q25 = 4.90 kPa; Q75 = 8 kPa) and a median SWE measurement of 7.00 kPa (Q25 = 6.10 kPa; Q75 = 8.10 kPa). We could observe a significant correlation between the FS and SWE measurements (0.49; P = .001) in the total cohort. The average absolute difference between the measurements of these 2 methods was of 2.54 kPa (sd = 3.39). There was no significant correlation for patients with NAFLD no matter whether they presented with signs of suspected non alcoholic steatohepatitis (NASH) or not (R = 0.20; P = .108). All patients intending to perform the examination were able to undergo the SWE, allowing 33.3% of the patients who failed the FS to have a noninvasive evaluation of their fibrosis | ||
| 520 | |a CONCLUSION: The SWE technique proved to be as efficient as the FS one for the evaluation of the liver fibrosis in real life situation | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Cadranel, Jean François David |e verfasserin |4 aut | |
| 700 | 1 | |a Fantognon, Gildas |e verfasserin |4 aut | |
| 700 | 1 | |a Azzi, Badia |e verfasserin |4 aut | |
| 700 | 1 | |a Smadhi, Ryad |e verfasserin |4 aut | |
| 700 | 1 | |a Ngele Efole, Jean René |e verfasserin |4 aut | |
| 700 | 1 | |a Mrabti, Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Heng, Ratmony |e verfasserin |4 aut | |
| 700 | 1 | |a Ntsama, Marie Adrienne |e verfasserin |4 aut | |
| 700 | 1 | |a Medmoun, Mourad |e verfasserin |4 aut | |
| 700 | 1 | |a Kazerouni, Firouzeh |e verfasserin |4 aut | |
| 700 | 1 | |a Le Magoarou, Tristan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicine |d 1945 |g 101(2022), 32 vom: 12. Aug., Seite e30025 |w (DE-627)NLM000020737 |x 1536-5964 |7 nnns |
| 773 | 1 | 8 | |g volume:101 |g year:2022 |g number:32 |g day:12 |g month:08 |g pages:e30025 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/MD.0000000000030025 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 101 |j 2022 |e 32 |b 12 |c 08 |h e30025 | ||